VER-01: The Cannabis Drug That Outperformed Opioids in Phase III Trials

For decades, the question of whether cannabis could replace opioids for chronic pain management has lingered somewhere between anecdotal promise and clinical uncertainty. A German pharmaceutical company called Vertanical may have just answered it.

VER-01, a full-spectrum cannabis extract developed by Vertanical, has completed two successful Phase III clinical trials demonstrating that it not only matches but outperforms opioids in treating chronic lower back pain. The data is the strongest clinical evidence to date that a cannabis-derived pharmaceutical can serve as a genuine alternative to opioid therapy, and it arrives at a moment when the global opioid crisis continues to claim tens of thousands of lives annually.

What Is VER-01

VER-01 is not a single-molecule drug like Epidiolex or Marinol. It is a standardized, full-spectrum cannabis extract that contains the complete range of cannabinoids, terpenes, and other bioactive compounds found in the cannabis plant. Vertanical's approach is built on the entourage effect hypothesis, the idea that cannabis compounds work more effectively together than in isolation.

The extract is formulated as an oral liquid taken in drops, designed to provide consistent dosing while preserving the synergistic pharmacology of the whole plant. If approved, VER-01 would be marketed under the brand name Exilby.

The Clinical Evidence

Two pivotal Phase III trials have established VER-01's efficacy profile. Together, they represent the most rigorous clinical evaluation of a cannabis-based pain treatment ever conducted.

The Placebo-Controlled Trial

The first Phase III study enrolled 820 patients with chronic non-specific lower back pain, one of the most common and difficult-to-treat pain conditions globally. Patients were randomized to receive either VER-01 or placebo over a 12-week treatment period.

The trial met its primary endpoint, demonstrating a statistically significant reduction in pain scores for the VER-01 group compared to placebo. The effect size was clinically meaningful, with patients reporting not only reduced pain intensity but also improved functional capacity and quality of life.

The ELEVATE Study: Head-to-Head Against Opioids

The second and more consequential trial was the ELEVATE study, a head-to-head comparison of VER-01 against standard opioid therapy in 384 patients with chronic lower back pain. This study design is unusual in cannabis research, where most trials compare against placebo rather than against an active comparator.

The ELEVATE trial met its primary efficacy endpoint, with VER-01 demonstrating pain relief that was at minimum equivalent to and in several measures superior to opioid treatment over a six-month period. But the safety data was where VER-01 truly distinguished itself.

Where VER-01 Beats Opioids

The advantages of VER-01 over opioid therapy extended well beyond equivalent pain relief.

Dramatically Lower Side Effect Burden

Patients receiving VER-01 were four times less likely to develop constipation than those receiving opioids, and three times less likely to require laxative use. Opioid-induced constipation is not merely an inconvenience. It is a clinically significant adverse effect that affects an estimated 40 to 80 percent of patients on long-term opioid therapy and is a leading reason patients discontinue treatment.

Improved Sleep Quality

Patients in the VER-01 arm reported sustained improvements in sleep quality throughout the six-month study period. Sleep disruption is a common comorbidity with chronic pain, and it represents a dimension of patient wellbeing that most analgesic treatments fail to address. The fact that VER-01 improved sleep while opioids did not is a notable clinical differentiator.

No Addiction Pathway

Perhaps the most significant advantage of VER-01 is what it does not do. Unlike opioids, which activate mu-opioid receptors and create well-documented dependency pathways, VER-01's pharmacological mechanism does not carry the same addiction risk. In an era where opioid use disorder affects an estimated 16 million people worldwide, a non-addictive alternative for chronic pain management represents a paradigm shift.

The Regulatory Path Forward

Vertanical is pursuing regulatory approval on two fronts simultaneously.

European and UK Market Entry

The company intends to seek regulatory approval in Europe and the United Kingdom in 2026, with a target of bringing VER-01 to market under the Exilby brand name as early as late 2026 or 2027. The European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency have both signaled increasing openness to evidence-based cannabis therapeutics, and VER-01's robust clinical data package is well-positioned to meet their evidentiary standards.

US FDA Pathway

A Phase III clinical trial in the United States is expected to begin in early 2026 to support a subsequent filing with the Food and Drug Administration. The recent rescheduling of medical cannabis to Schedule III under the Controlled Substances Act has created a more favorable regulatory environment for cannabis-based pharmaceuticals, though the FDA pathway will still require the company to demonstrate safety, efficacy, and manufacturing consistency under the agency's rigorous standards.

Beyond Back Pain

Vertanical is not limiting VER-01's potential to a single indication. The company is actively studying the extract as a pain treatment for osteoarthritis and peripheral neuropathy, two additional conditions where current treatment options are either inadequate or carry significant side effect risks.

Osteoarthritis affects an estimated 500 million people globally and is one of the leading drivers of opioid prescriptions. If VER-01 demonstrates similar efficacy in osteoarthritis trials, it could address a market that is orders of magnitude larger than chronic lower back pain alone.

Peripheral neuropathy, which causes pain, numbness, and weakness in the extremities, is another condition where existing treatments are often insufficient. Patients with diabetic neuropathy, chemotherapy-induced neuropathy, and other forms of the condition frequently cycle through multiple medications without finding adequate relief. A cannabis-based option could fill a significant unmet need.

What VER-01 Means for the Cannabis Industry

VER-01 is not a dispensary product. It is a pharmaceutical that will require a prescription and be subject to the same regulatory oversight as any other medicine. But its success in clinical trials sends a powerful signal to the broader cannabis industry and to skeptics of cannabis-based medicine.

Validating Full-Spectrum Approaches

Much of the pharmaceutical industry's interest in cannabis has focused on isolated compounds, particularly CBD and synthetic THC analogs. VER-01's success as a full-spectrum extract validates the argument that the whole plant offers therapeutic benefits that isolated molecules may not replicate. This finding could accelerate research into other full-spectrum formulations for different medical conditions.

Building Credibility with the Medical Establishment

The rigorous clinical trial data behind VER-01 addresses one of the most persistent criticisms of medical cannabis: that the evidence base is too thin to support clinical use. Two successful Phase III trials, including a head-to-head comparison against opioids, represent the kind of evidence that physicians, insurers, and regulators have long demanded before taking cannabis-based medicine seriously.

Implications for Insurance Coverage

If VER-01 gains regulatory approval as a prescription pharmaceutical, it would be eligible for insurance coverage in most jurisdictions. This is a critically important distinction from dispensary cannabis, which patients must purchase out of pocket. Insurance coverage would dramatically expand access to cannabis-based pain treatment for patients who cannot afford dispensary prices.

The Bigger Picture

The opioid crisis has killed more than 600,000 Americans since 1999 and continues to claim approximately 80,000 lives annually. Globally, the toll is even higher. Despite decades of awareness campaigns, prescription monitoring programs, and regulatory interventions, the crisis persists in large part because physicians have had few effective alternatives to offer patients with chronic pain.

VER-01 will not single-handedly solve the opioid crisis. No single drug could. But it represents something that has been missing from the conversation: a rigorously tested, non-addictive alternative that can match opioid efficacy without opioid consequences. If VER-01 reaches the market and performs in real-world clinical practice as well as it did in controlled trials, it could become one of the most important new tools in the fight against opioid dependency.

For the cannabis industry, VER-01 is proof of concept. For patients with chronic pain, it could be something much more meaningful: a way out.

Looking for a verified shop carrying products like these? Browse Budpedia's dispensary near me directory to find licensed cannabis retailers in your state with up-to-date menus.